Objective: The objective of this study was toevaluate the efficacy and tolerability of the rapid-acting i.m.formulation of the novel antipsychotic ziprasidone in thetreatment of inpatients with psychosis and acute agitation(DSM-IV diagnoses).
Method: In a 24-hour, double-blind, fixed-doseclinical trial, patients were randomly assigned to receive up to4 injections (every 2 hours p.r.n.) of 2 mg (N = 54) or 10 mg (N= 63) of ziprasidone i.m. The Behavioral Activity Rating Scalemeasured behavioral symptoms at baseline and the response totreatment up to 4 hours after the first i.m. injection.
Results: Ziprasidone i.m., 10 mg, rapidlyreduced symptoms of acute agitation and was significantly moreeffective (p < .01) than the 2-mg dose up to 4 hours after thefirst injection. Patients were calmed but not excessivelysedated, and over half were classed as responders 2 hours afterthe 10-mg dose. No acute dystonia or behavioral disinhibition wasreported. One patient who received the 10-mg dose experienced theextrapyramidal side effect akathisia.
Conclusion: Ziprasidone i.m., 10 mg, is rapidlyeffective and well tolerated in the short-term management of theagitated psychotic patient. Comparison with a study of identicaldesign comparing 2-mg with 20-mg doses in patients with similarlevels of psychopathology suggests that efficacy with 10 mg or 20mg of ziprasidone i.m. is significant and dose related.
Author Affiliations
Enjoy free PDF downloads as part of your membership!
Save
Cite